EirGenix is ramping up its new drug development efforts. Among the notable projects is the biosimilar for breast cancer treatment, EG12014, which comes in a 150mg lyophilized injection. Their partner, Sandoz, submitted a license application to the US FDA in June, with the review expected to be completed by the fourth quarter. Additionally, a 420mg dose is anticipated to be submitted to the FDA by Sandoz in the third quarter of next year, adding momentum to their operations.
Read more
